Insider Transactions and Merger Impact

This filing details significant insider transactions related to Crinetics Pharmaceuticals, Inc. (CRNX) following its merger with Vertex Pharmaceuticals Incorporated, effective September 1, 2026. Isabel Kalofonos, Chief Commercial Officer, reported the disposition of 1,669 shares of Common Stock acquired under the Employee Stock Purchase Plan, along with the disposition of 34,000 shares of Common Stock. Additionally, Kalofonos reported the disposition of stock options to buy 97,500 and 55,000 shares of Common Stock, with exercise prices of $44.41 and $41.21, respectively. These transactions occurred as part of the merger, where remaining unvested restricted stock units and stock options were vested and subsequently canceled, converting into the right to receive $85.00 per share in cash, or the difference between the merger consideration and the exercise price for vested options. All reported post-transaction share ownership is zero, indicating the completion of these transactions.